Derm In-Review

Derm In-Review Derm In-Review is the #1 Board and MOC prep with the largest Q&A bank.

Over 10 yrs., Derm In-Review has prepared 11,500+ residents and 10,000 dermatologists. Derm IN-Review is a product of Our mission is to continue to provide quality educational resources that help prepare physicians for their career and beyond. We intend to continue to live up to that tradition by causing as little a disruption in services as possible. For over a decade, Derm In-Review has prepared more than 10,500 residents for the Board certifying exams, and has provided educational resources to more than 9,000 dermatology healthcare professionals.

We would like to thank our sponsors, Sanofi Regeneron for their support of the Derm In-Review Digital Study Guide! The i...
02/18/2026

We would like to thank our sponsors, Sanofi Regeneron for their support of the Derm In-Review Digital Study Guide!

The iconic exam prep guide is available in PDF format for on-the-go study, whenever, wherever. The digital study guide also includes a bonus chapter: CME In-Review! Download it today: https://ow.ly/18Kj50Yh73F

Sanofi is a R&D driven, AI-powered biopharma company committed to improving people’s lives and creating compelling growth. Their team is guided by one purpose: to chase the miracles of science to improve people’s lives. https://ow.ly/rRQl50Yh73H Regeneron, a leading biotechnology company, develops medicines for serious diseases. Founded by physician-scientists, their ability to translate science into medicine has led to numerous FDA-approved treatments and investigational candidates. https://ow.ly/ZxgW50Yh73E

Pyoderma gangrenosum doesn’t always follow the bowel.PG is a rare, painful neutrophilic dermatosis classically linked to...
02/17/2026

Pyoderma gangrenosum doesn’t always follow the bowel.

PG is a rare, painful neutrophilic dermatosis classically linked to systemic disease—especially IBD. But this "Great Cases from the JDD" is a reminder that PG can develop even after total colectomy and in the absence of active bowel disease.

📌 Case highlight:
A 55-year-old woman developed peristomal PG one year after colectomy for ulcerative colitis, with rapidly progressive, painful ulcers despite a clean ostomy. Treatment with intralesional triamcinolone followed by systemic adalimumab led to marked improvement within weeks.
Learn why this matters and clinical takeaways by reading the full case study: https://ow.ly/pa5q50Yhhm6


FRIDAY POP QUIZ is live! Can you pick the correct answer? 🧠✨Drop your best choice in the comments, then head over to Nex...
02/13/2026

FRIDAY POP QUIZ is live! Can you pick the correct answer? 🧠✨
Drop your best choice in the comments, then head over to Next Steps in Derm to see if you got it right—complete with the correct answer and explanations for the other options.

Ready, set, guess! https://ow.ly/WHLX50Yf9xB

Thinking about life after residency can feel daunting. 😩Derm In-Review Advisory Council Member Dr. Kristan Schiele says ...
02/10/2026

Thinking about life after residency can feel daunting. 😩

Derm In-Review Advisory Council Member Dr. Kristan Schiele says thinking about her future left her anxious and unsure. She wished there was a decision tree or Bolognia chart that could help her navigate the transition from resident to attending.

In this Next Steps in Derm article, Dr. Schiele shares lessons she’s learned while in the interview process, including:

✨ Start early with honest reflection about your values and vision
✨ Explore broadly before narrowing (even paths you don’t think you want)
✨ In-person visits matter more than you expect—culture, flow, and people are everything

Read Dr. Schiele’s experience with job searching and gain practical tips and encouragement: https://ow.ly/4aLn50YbNGU


If each dermatology year were a song, what would the playlist be? 🎶Comment with: PGY‑1: __ | PGY‑2: __ | PGY‑3: __ | PGY...
02/10/2026

If each dermatology year were a song, what would the playlist be? 🎶

Comment with: PGY‑1: __ | PGY‑2: __ | PGY‑3: __ | PGY‑4: __ — and tag a co‑resident who needs this soundtrack. Best/funniest replies get a shoutout! ⬇️

(Need a spark? Example: PGY‑1: “Eye of the Tiger” 🐯)

Friday Pop Quiz is live! Can you guess the correct answer? Drop your best choice (A/B/C/D/E) in the comments — then head...
02/06/2026

Friday Pop Quiz is live! Can you guess the correct answer? Drop your best choice (A/B/C/D/E) in the comments — then head to Next Steps in Derm to see the correct answer and full explanations: https://ow.ly/2ArM50Y9UUf

No peeking 😉 Good luck!

Derm In-Review Advisory Council Member Dr. Jay Nguyen says choosing a community-based residency program is one of the mo...
02/02/2026

Derm In-Review Advisory Council Member Dr. Jay Nguyen says choosing a community-based residency program is one of the most important decisions he’s ever made.

In this Next Steps in Derm article, Dr. Nguyen outlines the benefits of community-based programs, including:

✨ High-volume, real-world outpatient care
✨ Exposure to diverse patient populations and payer mixes
✨ Early autonomy with continuity clinics
✨ Robust procedural experience (including Mohs & cosmetics)
✨ Hands-on practice management, billing, and leadership experience
✨ Ethical, practical interactions with industry partners

Learn more about this unique type of dermatology residency: https://ow.ly/Zjhq50Y7Gl4

Friday Pop Quiz! 🧠✨ Think you’ve got this one? Drop your best answer (A, B, C, D, or E) in the comments — no peeking! 👇T...
01/30/2026

Friday Pop Quiz! 🧠✨ Think you’ve got this one? Drop your best answer (A, B, C, D, or E) in the comments — no peeking! 👇

The correct choice — plus full explanations for why the other options are wrong — is now live on the Next Steps in Derm website. Head there to see if you nailed it: https://ow.ly/wtHB50Y64Mb

Ready. Set. Guess!

Benign Familial Pemphigus (Hailey-Hailey disease) can be devastating for patients—painful, relapsing fissures in flexura...
01/28/2026

Benign Familial Pemphigus (Hailey-Hailey disease) can be devastating for patients—painful, relapsing fissures in flexural areas, limited treatment options, and a profound impact on quality of life.

This Great Cases from the JDD highlights topical ruxolitinib 1.5% cream as a promising novel option for refractory HHD.

By targeting JAK-1 and JAK-2 and downregulating inflammatory cytokines such as IL-4, IL-6, and IL-13, topical JAK inhibition may help reduce inflammation, support wound healing, and minimize superinfection—without the systemic risks seen with oral agents.

While not yet FDA-approved for HHD, this case adds to growing evidence supporting its potential role in difficult-to-treat disease.

📖 Read the full case study: https://ow.ly/JTUV50Y4uSO

Friday Pop Quiz is live! Drop your best answer (A/B/C/D/E) in the comments — can you guess the correct answer? Then head...
01/23/2026

Friday Pop Quiz is live! Drop your best answer (A/B/C/D/E) in the comments — can you guess the correct answer? Then head over to Next Steps in Derm to see the right choice and full explanations:

https://ow.ly/zsCU50Y1QXU

Good luck! 🍀

Psoriasis is increasingly linked to systemic comorbidities—making effective, targeted treatment essential.While biologic...
01/21/2026

Psoriasis is increasingly linked to systemic comorbidities—making effective, targeted treatment essential.

While biologics targeting IL-23 and IL-17 have transformed care for many patients with moderate-to-severe disease, challenging subtypes like scalp and palmoplantar psoriasis can remain stubbornly recalcitrant.

In our Therapeutic Cheat Sheet series, we take a closer look at deucravacitinib—an FDA-approved option for adults with plaque psoriasis, with growing off-label use in conditions like cutaneous lupus and oral lichen planus: https://ow.ly/Nh6Z50Y0lFR

The Dermatology In-Review study guide is designed to bring the best and most comprehensive board review program around! ...
01/20/2026

The Dermatology In-Review study guide is designed to bring the best and most comprehensive board review program around! The study guide provides clinical guidelines, color coding for the Basic vs. Core exams, numerous kodies, and the latest and greatest in our therapeutic armamentarium.

We would like to thank our sponsor UCB for their support of this program !

Address

New York, NY

Telephone

(212) 213-5436

Website

Alerts

Be the first to know and let us send you an email when Derm In-Review posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Derm In-Review:

Shortcuts

Featured

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram